| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/JTO.0B013E318074DE34 |
| P698 | PubMed publication ID | 17603311 |
| P50 | author | Jun Itami | Q104585251 |
| P2093 | author name string | Masato Hareyama | |
| Tomoki Kimura | |||
| Hiroki Shirato | |||
| Tsutomu Araki | |||
| Masahiro Hiraoka | |||
| Hiroshi Onishi | |||
| Yoshihiro Takai | |||
| Masaki Kokubo | |||
| Kazushige Hayakawa | |||
| Katsuyuki Karasawa | |||
| Kazunari Yamada | |||
| Yuzuru Niibe | |||
| Atsuya Takeda | |||
| Ryusuke Hara | |||
| Yasushi Nagata | |||
| Masaharu Fujino | |||
| Atsushi Ouchi | |||
| Kotaro Gomi | |||
| P433 | issue | 7 Suppl 3 | |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| lung cancer | Q47912 | ||
| P304 | page(s) | S94-100 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study | |
| P478 | volume | 2 |
| Q38778226 | A Histologic Basis for the Efficacy of SBRT to the lung |
| Q36554195 | A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). |
| Q35960118 | A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience |
| Q41645384 | A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer |
| Q64071662 | A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer |
| Q36111869 | A decade of advances in treatment of early-stage lung cancer |
| Q51664383 | A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization. |
| Q57037450 | A hybrid planning strategy for stereotactic body radiation therapy of early stage non-small-cell lung cancer |
| Q41781300 | A millimeter miss is as good as a thousand miles: The role of accurate target localization in lung stereotactic body radiation therapy |
| Q36500052 | A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer |
| Q33847603 | A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 |
| Q32173730 | A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) |
| Q44011535 | A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer |
| Q48015363 | A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical On |
| Q89208601 | A simple method to account for skin dose enhancement during treatment planning of VMAT treatments of patients in contact with immobilization equipment |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q38413597 | Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : Ablative dose PBT for NSCLC. |
| Q57498590 | Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up |
| Q46271933 | Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing |
| Q30993385 | Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy. |
| Q92281611 | Adoption of Stereotactic Body Radiotherapy for Stage IA Non-Small Cell Lung Cancer Across the United States |
| Q33645619 | Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy |
| Q37767616 | Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time? |
| Q34337294 | American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer |
| Q87410539 | Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors |
| Q30585045 | Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy |
| Q64269417 | Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT) |
| Q37135670 | Anniversary paper: Role of medical physicists and the AAPM in improving geometric aspects of treatment accuracy and precision |
| Q61804642 | Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer |
| Q61583102 | Cancers bronchiques non à petites cellules localement avancés : quelle radiothérapie en 2014 ? |
| Q64922396 | Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI. |
| Q41432497 | Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges |
| Q38663392 | Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy |
| Q51171710 | Clinical impact of using the deterministic patient dose calculation algorithm Acuros XB for lung stereotactic body radiation therapy. |
| Q59125770 | Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer |
| Q30834087 | Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system |
| Q36101987 | Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence |
| Q34202715 | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
| Q48705863 | Combination effects of tissue heterogeneity and geometric targeting error in stereotactic body radiotherapy for lung cancer using CyberKnife |
| Q38245873 | Combination of stereotactic ablative body radiation with targeted therapies |
| Q26852202 | Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC |
| Q58614800 | Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer |
| Q38685007 | Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy. |
| Q47446694 | Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer. |
| Q29248456 | Comparison of Two RapidArc Delivery Strategies in Stereotactic Body Radiotherapy of Peripheral Lung Cancer with Flattening Filter Free Beams |
| Q38170954 | Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation |
| Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
| Q91323191 | Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience |
| Q38914996 | Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. |
| Q55653104 | Comparison of the progressive resolution optimizer and photon optimizer in VMAT optimization for stereotactic treatments. |
| Q26995851 | Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| Q42116312 | Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response |
| Q52763791 | Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study. |
| Q90095163 | Correlation of normal lung density changes with dose after stereotactic body radiotherapy (SBRT) for early stage lung cancer |
| Q28950857 | Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy |
| Q37004652 | CyberKnife robotic radiosurgery system for tumor treatment |
| Q36186315 | DNA topoisomerase I drugs and radiotherapy for lung cancer |
| Q35796322 | Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting |
| Q36128358 | Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer |
| Q41872325 | Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose |
| Q93160441 | Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer |
| Q60908706 | Developments in Stereotactic Body Radiotherapy |
| Q41857918 | Diagnosis, staging and treatment of patients with non-small cell lung cancer for the surgeon. |
| Q91675470 | Difference in Acquired Radioresistance Induction Between Repeated Photon and Particle Irradiation |
| Q36661346 | Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer |
| Q37672787 | Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review |
| Q33574732 | Does Motion Assessment With 4-Dimensional Computed Tomographic Imaging for Non-Small Cell Lung Cancer Radiotherapy Improve Target Volume Coverage? |
| Q44560526 | Dose calculation differences between Monte Carlo and pencil beam depend on the tumor locations and volumes for lung stereotactic body radiation therapy |
| Q40176468 | Dose differences in intensity-modulated radiotherapy plans calculated with pencil beam and Monte Carlo for lung SBRT. |
| Q57456149 | Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): a multi-arm phase I trial |
| Q37152509 | Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial |
| Q99582784 | Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis |
| Q30421587 | Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer |
| Q36279626 | Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer |
| Q42321832 | Dosimetric evaluation of the impacts of different heterogeneity correction algorithms on target doses in stereotactic body radiation therapy for lung tumors |
| Q40496623 | Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer |
| Q28730322 | Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases |
| Q37789035 | Early detection and screening of lung cancer |
| Q64969902 | Early stage lung cancer survival after wedge resection and stereotactic body radiation. |
| Q38696970 | Enhancement of mTOR signaling contributes to acquired X-ray and C-ion resistance in mouse squamous carcinoma cell line |
| Q33860897 | Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer |
| Q47332027 | Evaluating which plan quality metrics are appropriate for use in lung SBRT. |
| Q51286974 | Evaluation of 4D dose to a moving target with Monte Carlo dose calculation in stereotactic body radiotherapy for lung cancer. |
| Q47097838 | Evaluation of ray tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers |
| Q57175083 | Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham's (UK) Experience |
| Q28282037 | Exploring the role of cancer stem cells in radioresistance |
| Q37131693 | Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer |
| Q34366580 | Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume |
| Q38917758 | Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce |
| Q48794414 | Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy. |
| Q99582898 | Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer |
| Q37672027 | Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer. |
| Q33402602 | High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study |
| Q37114850 | High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study |
| Q83182085 | High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer |
| Q44070976 | Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group |
| Q89354934 | Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy |
| Q36840379 | Hypofractionated radiotherapy for medically inoperable stage I non-small cell lung cancer |
| Q52716524 | Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a 10-year single institution experience. |
| Q36949855 | Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain. |
| Q91868558 | Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors |
| Q90313120 | Impact of the Time Proportion of Respiratory Phases on Dosimetry in SBRT of Lung Tumor Near the Chest Wall or Diaphragm |
| Q30985297 | Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data |
| Q40116176 | Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy. |
| Q50050064 | Influence of patient characteristics on survival following treatment with helical stereotactic body radiotherapy (SBRT) in stage I non-small-cell lung cancer |
| Q47141026 | Institutional experience on the treatment of lung and liver lesions with stereotactic body radiotherapy and Novalis Exactrac Adaptive Gating technique |
| Q38243178 | Integrating stereotactic body radiation therapy in stage II/III non-small cell lung cancer: is local control important? |
| Q36621168 | Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer |
| Q35980883 | Inter-Fraction Tumor Volume Response during Lung Stereotactic Body Radiation Therapy Correlated to Patient Variables |
| Q38051243 | Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? |
| Q37774973 | Limited resection followed by intraoperative seed implantation is comparable to stereotactic body radiotherapy for solitary lung cancer. |
| Q84587869 | Limited resection for early-stage lung cancer |
| Q36222951 | Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). |
| Q36445513 | Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? |
| Q64078812 | Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer |
| Q93111716 | Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer |
| Q44130820 | Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. |
| Q47149089 | Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer |
| Q33805678 | Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy |
| Q26827382 | Lung cancer ablation: technologies and techniques |
| Q47121935 | Lung reirradiation with stereotactic body radiotherapy (SBRT). |
| Q38635201 | Markov chain Monte Carlo analysis for the selection of a cell-killing model under high-dose-rate irradiation |
| Q35710141 | Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy |
| Q37472654 | Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study |
| Q39186802 | Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: A review from NRG oncology |
| Q40656245 | Multicenter prospective study of sublobar resection for c-stage I non-small cell lung cancer patients unable to undergo lobectomy (KLSG-0801): complete republication |
| Q38087689 | New era of radiotherapy: an update in radiation-induced lung disease. |
| Q37670432 | New techniques for assessing response after hypofractionated radiotherapy for lung cancer |
| Q34167597 | Non-surgical management of stage I lung cancer |
| Q33887571 | Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy |
| Q37667254 | Oligometastases and oligo-recurrence: the new era of cancer therapy |
| Q33826696 | Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors |
| Q59587525 | Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy |
| Q44848976 | Particle therapy for clinically diagnosed stage I lung cancer: comparison with pathologically proven non-small cell lung cancer |
| Q64267035 | Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer |
| Q47651774 | Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. |
| Q34193728 | Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer |
| Q81574278 | Percutaneous radiofrequency ablation of lung cancer |
| Q48202266 | Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). |
| Q60908672 | Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma |
| Q64277127 | Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer |
| Q92602008 | Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer |
| Q58735972 | Pretreatment F-fluorodeoxyglucose Uptake in the Lung Parenchyma Predicts Poor Survival After Stereotactic Body Radiation Therapy in Patients With Stage I Non-Small Cell Lung Cancer |
| Q37581256 | Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy |
| Q26851601 | Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients |
| Q91830232 | Prognostic Role Of Computed Tomography Textural Features In Early-Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy |
| Q36524133 | Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis |
| Q34187098 | Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer |
| Q50050183 | Proton therapy for non-small cell lung cancer: Current evidence and future directions |
| Q55420726 | Proton therapy in non-small cell lung cancer. |
| Q38241214 | Proton-based stereotactic ablative radiotherapy in early-stage non-small-cell lung cancer |
| Q92040126 | Questionnaire survey on treatment planning techniques for lung stereotactic body radiotherapy in Japan |
| Q37367501 | Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules |
| Q36655289 | Radiation dose-volume effects in the esophagus |
| Q37007890 | Radiation therapy for early stage lung cancer |
| Q95841272 | Radiation-Induced Secondary Cancer Risk Assessment in Patients With Lung Cancer After Stereotactic Body Radiotherapy Using the CyberKnife M6 System With Lung-Optimized Treatment |
| Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
| Q36363955 | Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy |
| Q33787072 | Radiofrequency ablation for early-stage nonsmall cell lung cancer |
| Q47095312 | Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). |
| Q88590631 | Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose |
| Q42109226 | Radiotherapy for Oligometastatic Lung Cancer |
| Q94592974 | Radiotherapy in Lung Cancer: Current and Future Role |
| Q40010886 | Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study |
| Q38390164 | Recurrence after surgery in patients with NSCLC. |
| Q34000975 | Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. |
| Q49467909 | Repeated photon and C-ion irradiations in vivo have different impact on alteration of tumor characteristics. |
| Q33571109 | Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs) |
| Q35541222 | Rib fracture after stereotactic radiotherapy on follow-up thin-section computed tomography in 177 primary lung cancer patients |
| Q45051768 | Risk factors for postoperative complications in the elderly with lung cancer |
| Q49356117 | Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using stereotactic body radiotherapy (SBRT) in locally advanced non-small cell lung cancer (NSCLC). |
| Q37566614 | Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer |
| Q35200592 | SBRT in operable early stage lung cancer patients. |
| Q33786992 | Safety and efficacy of intensity-modulated stereotactic body radiotherapy using helical tomotherapy for lung cancer and lung metastasis |
| Q38161371 | Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team |
| Q49650935 | Selection of external beam radiotherapy approaches for precise and accurate cancer treatment |
| Q60917984 | Simulation of dosimetry impact of 4DCT uncertainty in 4D dose calculation for lung SBRT |
| Q53138445 | Simultaneous computed tomography-guided biopsy and radiofrequency ablation of solitary pulmonary malignancy in high-risk patients. |
| Q59587510 | Stage I nonsmall cell lung cancer in patients aged ≥75 years |
| Q37614564 | State-of-the-art lung cancer radiation therapy |
| Q37902239 | Status of particle therapy for lung cancer |
| Q57764566 | Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study |
| Q64248763 | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series |
| Q53062109 | Stereotactic Body Radiotherapy Versus Surgery for Medically Operable Stage I Non–Small-Cell Lung Cancer: A Markov Model–Based Decision Analysis |
| Q37784902 | Stereotactic Radiosurgery for Lung Tumors |
| Q47140283 | Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control |
| Q36286591 | Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours |
| Q98289160 | Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung |
| Q41112569 | Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard |
| Q84443095 | Stereotactic ablative radiotherapy for inoperable stage I NSCLC |
| Q97537795 | Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review |
| Q44020055 | Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity |
| Q35667829 | Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies |
| Q42427013 | Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer |
| Q91631990 | Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial |
| Q57172947 | Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances |
| Q89005809 | Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) |
| Q36550532 | Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity |
| Q37822743 | Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy |
| Q57177641 | Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions |
| Q38068588 | Stereotactic body radiation therapy for metastasis to the adrenal glands |
| Q60912983 | Stereotactic body radiation therapy for non-small cell lung cancer: A review |
| Q34368868 | Stereotactic body radiation therapy for stage I non-small cell lung cancer: a small academic hospital experience |
| Q64096283 | Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications |
| Q34859171 | Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity |
| Q91738877 | Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid |
| Q37123115 | Stereotactic body radiation therapy: transcending the conventional to improve outcomes |
| Q89530701 | Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients |
| Q58788717 | Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the "no fly" zone |
| Q35646076 | Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry |
| Q61804651 | Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer |
| Q35143839 | Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry |
| Q38059705 | Stereotactic body radiotherapy for metachronous multisite oligo-recurrence: a long-surviving case with sequential oligo-recurrence in four different organs treated using locally radical radiotherapy and a review of the literature |
| Q37222099 | Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results |
| Q49356651 | Stereotactic body radiotherapy for stage I non-small cell lung cancer |
| Q26781806 | Stereotactic body radiotherapy in lung cancer: an update |
| Q90701467 | Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity |
| Q82084588 | Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study |
| Q36734816 | Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer |
| Q90591596 | Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer |
| Q38175120 | Stereotactic body radiotherapy: a critical review for nonradiation oncologists |
| Q34163370 | Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib |
| Q37527522 | Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer |
| Q28085744 | Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions |
| Q39320180 | Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan® |
| Q44121610 | Stereotactic radiotherapy using tomotherapy for early-stage non-small cell lung carcinoma: analysis of intrafraction tumour motion |
| Q38226816 | Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond |
| Q57864954 | Surgery SBRT in retrospective analyses: confounding by operability is the elephant in the room |
| Q26863046 | Surgery in 2013 and beyond |
| Q38367507 | Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? |
| Q42354883 | Surgery versus SABR for early stage non-small cell lung cancer: the moving target of equipoise |
| Q26748296 | Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more |
| Q48369218 | Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. |
| Q90138365 | Survival of Primary SBRT Compared to Surgery for Operable Stage I/II Non-Small Cell Lung Cancer |
| Q48507372 | TEMPORARY REMOVAL: Local Control After Stereotactic Body Radiation Therapy for Liver Tumors |
| Q93483990 | The 4th Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake |
| Q30443893 | The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy |
| Q89892410 | The abscopal effect 67 years later: from a side story to center stage |
| Q53202349 | The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer. |
| Q51304164 | The cryoablation of lung tissue using liquid nitrogen in gel and in the ex vivo pig lung. |
| Q38625125 | The evolving role of radiotherapy in treatment of oligometastatic NSCLC. |
| Q92807807 | The irregular breathing effect on target volume and coverage for lung stereotactic body radiotherapy |
| Q26799892 | The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer |
| Q90655326 | The role of radiation therapy in the treatment of metastatic cancer |
| Q35113011 | The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms |
| Q37743289 | The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient? |
| Q37178916 | The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy |
| Q90407151 | Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response |
| Q35050966 | Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer |
| Q47163187 | Treating locally advanced lung cancer with a 1.5T MR-Linac - Effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy. |
| Q39371182 | Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer |
| Q37589200 | Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials |
| Q64118469 | Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy |
| Q26853124 | Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? |
| Q93369476 | Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors |
| Q38016163 | Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers |
| Q41677756 | Use of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning for Lung Cancer |
| Q92860034 | Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases |
| Q89688144 | Utilization of Stereotactic Ablative Body Radiation Therapy for Intact Renal Cell Carcinoma: Trends in Treatment and Predictors of Outcome |
| Q38172228 | What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer |
| Q92467682 | Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate |
| Q53288911 | [Effects of thymosin alpha-1 on radiation-induced pneumonitis]. |
| Q55441727 | [Radiation pneumonitis after stereotactic body radiation therapy for early stage non-small cell lung cancer]. |
| Q53288899 | [Stereotactic body radiaton therapy for 15 patients with small lung neoplasms]. |
Search more.